Home › Trials › NCT06780254
Clinical trial No longer in our active list Phase 1 Interventional Ages 18 to 65

Evaluating the safety and tolerability of MH-001 in healthy volunteers

Official title: A Two-Part Randomized Double-Blinded Placebo-Controlled, Phase 1 Study of Single and Multiple Ascending Doses of MH-001 in Healthy Participants

Run by Vespina Lifesciences Inc. · NCT06780254 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is testing a new drug called MH-001 in healthy volunteers to see how it works in the body and if it’s safe to use.

More Healthy Aging trials

Quick facts

PhasePhase 1
Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment64 (estimated)
SponsorVespina Lifesciences Inc.
Industry-sponsored
Locations1 site (Quebec)
Trial IDNCT06780254 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are healthy male or non-childbearing potential female volunteers with a BMI between 18.5 and 32.0 kg/m².

Probably not a fit

Patients with a history of significant medical illnesses or those with clinically significant laboratory abnormalities may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the pharmacokinetics, safety, and tolerability of MH-001 through single- and multiple-ascending doses administered to healthy volunteers. It is a first-in-human trial designed to gather essential data on how the drug behaves in the body and its potential side effects. Participants will receive either the drug or a placebo, and their health will be closely monitored throughout the study. The findings will help determine the appropriate dosing and safety profile for future studies.

Why it matters

Potential benefit: If successful, this study could provide critical safety and dosing information for MH-001, paving the way for its use in treating various conditions.

How similar studies have gone: Other first-in-human studies have shown success in establishing safety and pharmacokinetics for new drugs, making this approach a standard practice in drug development.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Male or non-childbearing potential Female, non smoker, with a Body Mass Index (BMI) between 18.5 and 32.0 kilogram per meter square (kg/m2) and red blood cells greater or equal (≥) to 120 grams per liter (g/L) for women and ≥135 g/L for men
* In good health, determined by no clinically significant findings of skin, dental, neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease

Exclusion Criteria:

* Have a history or presence of clinically significant medical illness including, but not limited to, any cardiovascular, hepatic, respiratory, hematological, chronic or relevant acute infections, relevant immunodeficiency, renal, endocrine, psychiatric or neurological disease, or any clinically significant laboratory abnormality that, in the judgment of the Investigator, indicates a medical problem that would preclude study participation.
* History of skin disorders including clinically significant active skin disease.
* History/signs and symptoms of current or recurrent teeth and gums disease
* Clinically significant abnormal laboratory test results or positive hepatitis panel and/or positive human immunodeficiency virus test.

Where it's running

  • Syneos Health clinic
    Quebec, Canada     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.